The most professional precise tumor diagnosis and treatment platform in China

•Since its establishment in 2016, BGI has been a precision medical company engaged in high-tech research and development and clinical application transformation in the field of cancer, committed to providing precision medical solutions for cancer patients, and as a close partner of biomedical companies, accelerating their drug development based on biomarkers. 

•Business model: clinical testing, pharmaceutical enterprise cooperation, gene big data. 

•Intellectual property rights: 16 software copyrights and 11 patents in the aspects of Biotrust algorithm, knowledge base construction, process integration, etc. 

•Core technologies: OriFuel algorithm (fusion), OriLongIndel algorithm (large segment insertion/deletion), OriTMB/OriMSI/OriRNA two-way multi module analysis system. 

•To this qualification: the Bioinformatics Analysis Team of Cancer Gene Proteomics China Research Center (the only one in China) of the US "Moon Landing Program", the official certification of the American Association of Pathologists (CAP), the American Clinical Laboratory Improvement Act Amendment (CLIA) certification issued by the US Federal Medical Insurance and Medical Assistance Service Center, the national high-tech enterprises, CSCO group membersFull score: passed the external quality assessment of various tumors at home and abroad by high-throughput sequencing. 

•In 2020, SciNova Fund invested 20 million yuan to coach the securities dealer: CICC Securities.